Eventide Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Eventide Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-436,000	Closed	-$4.1M	–	135
2018 Q4	$4.1M	Sell	436,000 -267,425	-38%	-$3.43M	0.18%	90
2018 Q3	$13.3M	Hold	703,425	–	–	0.49%	66
2018 Q2	$13.7M	Hold	703,425	–	–	0.57%	65
2018 Q1	$13.2M	Hold	703,425	–	–	0.62%	58
2017 Q4	$11.7M	Buy	703,425 +142,000	+25%	+$2.43M	0.61%	58
2017 Q3	$11.6M	Buy	561,425 +261,425	+87%	+$2.95M	0.66%	56
2017 Q2	$2.69M	Hold	300,000	–	–	0.17%	89
2017 Q1	$3.97M	Hold	300,000	–	–	0.26%	78
2016 Q4	$3.82M	Hold	300,000	–	–	0.25%	78
2016 Q3	$3.6M	Hold	300,000	–	–	0.22%	78
2016 Q2	$3.3M	Hold	300,000	–	–	0.2%	80
2016 Q1	$2.62M	Buy	300,000 +50,000	+20%	+$567K	0.15%	96
2015 Q4	$5.47M	Buy	+250,000	New	+$5.76M	0.27%	83

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Eventide Asset Management's VYGR Position: Q1 2019 in Review

Eventide Asset Management sold out of Voyager Therapeutics (VYGR) in Q1 2019, closing a stake of 436,000 shares — an estimated $4.1M sold.

Eventide Asset Management first reported a position in VYGR in Q4 2015 and held it in 13 quarters. The position peaked at $13.7M in Q2 2018. 111 funds tracked by Wall St. Rank hold VYGR as of Q1 2019.

Eventide Asset Management reported no remaining Voyager Therapeutics position as of Q1 2019 after selling out during the quarter.
Eventide Asset Management sold 436,000 Voyager Therapeutics shares in Q1 2019, an estimated $4.1M.
Eventide Asset Management first reported a position in Voyager Therapeutics in Q4 2015 and held it in 13 quarters.
Eventide Asset Management's Voyager Therapeutics position peaked at $13.7M in Q2 2018.
111 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2019.

Based on Eventide Asset Management's 13F filing for Q1 2019, filed 15 May 2019.